Home Test to Treat program extends nationwide

Program now offers testing, telehealth and treatment for COVID-19 and flu.Home Test to Treat logo

What

The federal government has expanded the Home Test to Treat program, an entirely virtual community health program that offers free COVID-19 health services: at-home rapid tests, telehealth sessions and at-home treatments, to eligible participants nationwide.

With its expansion, the Home Test to Treat program will now offer free testing, telehealth and treatment for both COVID-19 and for influenza (flu) A and B. It is the first public health program that includes home testing technology at such a scale for both COVID-19 and flu. The program initially will provide the LUCIRA® by Pfizer COVID-19 & Flu Home Test, the first U.S. Food and Drug Administration-authorized test that can detect both viruses in a single test at home.

For those indicated, treatment must begin within a limited window from onset of symptoms, underscoring the importance of continuity of care, from diagnosis to treatment. In addition, providing these services virtually, while individuals remain at home, is intended to expedite the time to treatment and the convenience of accessing services virtually from home.

Any adult (18 years and older) with a current positive test for COVID-19 or flu can enroll to receive free telehealth care and, if prescribed, medication delivered to their home. Adults who do not have COVID-19 or flu may enroll and receive free tests if they are uninsured or are enrolled in Medicare, Medicaid, Veterans Affairs health care system, or the Indian Health Services. If recipients test positive at a future time, they can receive free telehealth care and, if prescribed, treatment.

Visit Home Test to Treat(link is external) for more information.


This post is an excerpt from National Institutes of Health media release from December 6, 2023, Home Test to Treat program extends nationwide.

This entry was posted in COVID News, Health Promotion and tagged , , . Bookmark the permalink.

Comments are closed.